June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Comparison between intravitreal injection of ranibizumab to dexamethasone implant for macular edema secondary to central retinal vein occlusion.
Author Affiliations & Notes
  • leblanc alice
    ophtalmology, CHU POITIERS, Poitiers, France
  • Emilie Matamoros
    ophtalmology, CHU POITIERS, Poitiers, France
  • Nicolas Leveziel
    ophtalmology, CHU POITIERS, Poitiers, France
  • Footnotes
    Commercial Relationships leblanc alice, None; Emilie Matamoros, None; Nicolas Leveziel, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 199. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      leblanc alice, Emilie Matamoros, Nicolas Leveziel; Comparison between intravitreal injection of ranibizumab to dexamethasone implant for macular edema secondary to central retinal vein occlusion.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):199.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The aim of this study was to compare the efficacy and safety of intravitreal injection of ranibizumab (IRI) to dexamethasone implant (IDI) for the treatment of macular edema due to central retinal vein occlusion in a daily clinical setting.

Methods: Retrospective analysis of patients treated with either intravitreal ranibizumab injections or intravitreal dexamethasone implant for central retinal occlusion. Furthermore, visual acuity outcomes, central retinal thickness variation, the number of injections and number of switch toward other treatment were evaluated during the follow-up.

Results: 34 eyes of 30 patients with macular edema due to central retinal vein occlusion and followed for at least 6 months were included in the analysis. The mean age of the patients was 69,6 years. The mean improvement from baseline BCVA at month 6 was +1,3/10° in the intravitreal Ranibizumab injection group and +3,8/10° in intravitreal dexamethasone implant group. The mean reduction in CRT from baseline at month 6 was 278,3 microns in the IRI group and 288,3 microns in the IDI group. Ocular hypertension occurred in 2 eyes IDI. A switch in the treatment occurred in 6 eyes.

Conclusions: Intravitreal dexamethasone implant provided greater visual benefit and reduction CRT at month 6 than intravitreal ranibizumab injection in eyes with macular edema secondary to central retinal vein occlusion.<br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×